Osphena® improved three measures of vaginal health in 12 weeks1,2,3Some patients saw results as early as Week 4 (secondary endpoints)2,3,4

Osphena® improved three measures of vaginal health in 12 weeks1,2,3Some patients saw results as early as Week 4 (secondary endpoints)2,3,4

Study design : Three 12-week, randomized, double-blind, placebo-controlled, parallel group studies in post meopausal women. 1,2

Statistically significant results seen with Osphena®:1

  • Increase in the proportion of superficial cells (p<0.0001)
  • Decrease in the proportion of parabasal cells (p<0.0001)
  • Reduction in vaginal pH (p<0.0001)

Graphic representation of study results at Week 12*

graph 12weeks

*For illustration purposes only. Individual results may vary.

LS mean change from baseline to Week 12 in percentage of superficial and parabasal cells in vaginal smears (mITT populations; MMRM analysis)2

   %
Superficial
cells
%
Parabasal
cells
Study 12 Placebo N=90 1.6 -2.3
Ospemifene 60 mg N=109 11.6 -27.4
Study 22 Placebo N=146 3.6 -4.2
Ospemifene 60 mg N=148 13.3 -34.6
Study 32 Placebo N=241 1.8 -3.4
Ospemifene 60 mg N=247 9.5 -27.4

LS: least squares; mITT: modified intent-to-treat; MMRM: Mixed-effects Model Repeated Measure

Studies 2 and 3: dryness strata data (comparable changes observed with dyspareunia strata)

Osphena® significantly improved vaginal pH in 12 weeks or less1,2,3

Osphena® significantly decreased vaginal pH by Week 12 in three clinical trials.*,†,1,2

LS mean change from baseline to Week 12 in vaginal pH (mITT populations; MMRM analysis)2

efficacy vaginal dryness graph

LS: least squares; mITT: modified intent-to-treat; MMRM: Mixed-effects Model Repeated Measure

Women in both treatment groups were instructed to use vaginal lubricant as needed.

*Inclusion criteria: Vaginal pH more than 5.0 at baseline.1

p<0.0001 in all studies

Patients reported statistically significant* improvements in moderate to severe vaginal dryness with Osphena®3

Osphena® relieved vaginal dryness symptoms by Week 12.1,3

In a multicenter, double-blind, Phase 3 clinical trial in 631 women with moderate to severe vaginal dryness due to menopause, Osphena® significantly improved symptoms of vaginal dryness at Week 12 (-1.29 vs. -0.91 placebo; p<0.0001).1,3

From Weeks 4 (secondary endpoints) to 12 (primary endpoints), an increasing number of patients reported feeling improvements in the MBS vaginal dryness severity score versus placebo.

At baseline, women rated their most bothersome symptom of vaginal dryness on a 4-point scale: 0=none; 1=mild; 2=moderate; 3=severe.3

  • A 3-point improvement means a change from severe dryness to no dryness. Only patients who had severe dryness at baseline could report a 3-point change.
  • A 2-point improvement could be a change from severe to mild dryness, or from moderate to no dryness.

Changes in vaginal dryness severity scores (ITT population)**3

efficacy vaginal dryness graph

ITT: intent to treat

*p<0.0001

†Women who reported moderate or severe vaginal dryness as their most bothersome symptom, who had 5% or lesser superficial cells on their vaginal wall smear and a vaginal pH of more than 5.0 were eligible to participate.

‡Assessed on a 4-point scale (0, none; 1, mild; 2, moderate; 3, severe) using a validated, patient self-assessment of VVA questionnaire.

§Secondary endpoints.

¶Responders defined as those with improvements from baseline in the maturation value of 10 points, in vaginal pH of 0.5, and in the most bothersome symptom of vaginal dryness of 1 point.

**Similar results are seen in the mITT population.

Common side effects may include:1

  • Hot flashes
  • Vaginal discharge
  • Muscle spasms
  • Hyperhidrosis
  • Night sweats
  • Headaches
  • Vaginal hemorrhage

By Week 12:3

twice as many women taking Osphena® saw improvements in vaginal dryness vs. those taking placebo (odds ratio 2.23, 95% CI: 1.62–3.06) with Osphena®; and

five times as many Osphena® patients responded to therapy vs. those taking placebo (31.5% vs. 6.0%; p<0.0001).

Patients reported statistically significant* improvements in moderate to severe dyspareunia after treatment with Osphena®1

Osphena® relieved dyspareunia symptoms by Week 12.1

In two randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies in women with moderate to severe dyspareunia due to menopause, Osphena® significantly improved patients’ most bothersome symptom of moderate to severe dyspareunia.1

Change in dyspareunia severity score from baseline to Week 12 (LOCF; mITT population)1

about vva dyspareunia

mITT: modified intent to treat; LOCF: last observation carried forward; LS: least squares; SE: standard error

*p=0.0012, p<0.0001

†Women who reported moderate or severe dyspareunia as their most bothersome symptom, who had 5% or lesser superficial cells on their vaginal wall smear and a vaginal pH of more than 5.0 were eligible to participate.

Osphena® is contraindicated in patients with:1

  • Undiagnosed abnormal genital bleeding
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions
  • Active arterial thromboembolic disease (for example, stroke and myocardial infarction [MI]), or a history of these conditions
  • Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to Osphena® or any of its ingredients
  • Known or suspected pregnancy
  1. Osphena Prescribing Information. January 2019.
  2. Data on file. Duchesnay USA Inc.
  3. Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.
  4. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486.

Indication and Important Safety Information including Boxed Warning

INDICATIONS:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).

CONTRAINDICATIONS

  • Undiagnosed abnormal genital bleeding
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis (DVT), pulmonary embolism (PE) or a history of these conditions
  • Active arterial thromboembolic disease (e.g., stroke and myocardial infarction) or a history of these conditions
  • Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to OSPHENA or any of its ingredients
  • OSPHENA is contraindicated in women who are or may become pregnant. OSPHENA may cause fetal harm when administered to a pregnant woman. Ospemifene was embryo-fetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures, and embryo-fetal lethal in rabbits at 10 times the clinical exposure based on mg/m. If this drug is used during pregnancy, or if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus.

WARNINGS AND PRECAUTIONS

Cardiovascular Disorders

In the clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively in OSPHENA 60 mg treatment group and 3.15 and 0 per thousand women years in placebo. Should thromboembolic or hemorrhagic stroke occur or be suspected, OSPHENA should be discontinued immediately.

In the OSPHENA clinical trials, two cases of myocardial infarctions (MI) occurred in women receiving 60 mg of ospemifene.

In the OSPHENA clinical trials, two cases of DVT occurred in women receiving OSPHENA 60 mg. Should a VTE occur or be suspected, OSPHENA should be discontinued immediately.

If feasible, OSPHENA should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization.

Malignant Neoplasms

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has agonistic effects. In the OSPHENA clinical trials (60 mg treatment group), no cases of endometrial cancer were seen with exposure up to 52 weeks. There was a single case of simple hyperplasia without atypia. Endometrial thickening equal to 5 mm or greater was seen in the OSPHENA up to 52 weeks treatment groups at a rate of 101.4 per thousand women vs. 20.9 per thousand women for placebo. The incidence of any type of proliferative (weakly plus active plus disordered) endometrium was 26.3 per thousand women in the OSPHENA up to 52 weeks treatment groups vs. 0 per thousand women for placebo. Uterine polyps occurred at an incidence of 19.6 per thousand women in the OSPHENA up to 52 weeks treatment groups vs. 8.3 per thousand women for placebo.

An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The greatest risk appears to be associated with prolonged use and estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. The use of with OSPHENA therapy was not evaluated in the clinical trials.

OSPHENA 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer.

Severe Hepatic Impairment

OSPHENA should not be used in women with severe hepatic impairment.

In clinical trials, the more commonly reported adverse reactions in ≥1 percent of patients treated with OSPHENA 60 mg compared to placebo were:

  1. In 12-week, double blind, placebo-controlled clinical trials were hot flush (6.5% vs. 2.6%), vaginal discharge (3.8% vs. 0.4%), muscle spasms (1.8% vs. 0.6%) and hyperhidrosis (1.1% vs. 0.2%)
  2. In all clinical trials up to 52-weeks (safety population) were headaches (2.8% vs. 2.4%), hot flush (12.2% vs. 4.2%), muscle spasms (4.5% vs. 2.4%), hyperhidrosis (2.5% vs. 1.8%), night sweats (1.2% vs. 0.0%), vaginal discharge (6.00% vs. 0.6%) and vaginal hemorrhage (1.3% vs. 0.0%).

The following adverse reactions have been identified during post-approval use of ospemifene:

  • Neoplasms Benign, Malignant and Unspecified (including cysts and polyps); endometrial hyperplasia, endometrial cancer.
  • Immune System Disorders: allergic conditions including hypersensitivity, angioedema
  • Nervous System Disorders: headache
  • Vascular Disorders: deep vein thrombosis, thrombosis, pulmonary embolism
  • Skin and Subcutaneous Tissue Disorders: rash, rash erythematous, rash generalized, pruritus, urticaria

Drug interactions: OSPHENA is primarily metabolized by CYP3A4 and CYP2C9. CYP2C19 and other pathways contribute to the metabolism of ospemifene. Do not use estrogens or estrogen agonists/antagonists, fluconazole, ketoconazole or rifampin concomitantly with OSPHENA. Co-administration of OSPHENA with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of OSPHENA-related adverse reactions. OSPHENA is highly protein bound. Use cautiously with highly protein bound drugs as use with other highly protein-bound drugs may lead to increase exposure of that drug or ospemifene.

Please see Full Prescribing Information for OSPHENA (ospemifene) tablets, including Boxed Warning, regarding Endometrial Cancer and Cardiovascular Disorders, and Patient Information at osphena.com/hcp.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).